930596-35-3

Basic information

• Product Name: (1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate
• CAS NO: 930596-35-3
• Molecular Weight: 257.33
• Mol File: 930596-35-3.mol

Chemical Properties

• CAS DataBase Reference: (1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate(930596-35-3)
• EPA Substance Registry System: (1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate(930596-35-3)

Safety Data

• Hazardous Substances Data: 930596-35-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate is used as a key building block for the development of pharmaceuticals. Its unique structure allows for the creation of complex molecules with potential therapeutic effects. The protecting group in its structure enables selective reactions, which is crucial for the synthesis of specific drug candidates.
Used in Agrochemical Production:
In the agrochemical industry, (1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate is utilized as a fundamental component in the synthesis of various agrochemicals. Its ability to participate in selective reactions contributes to the development of effective compounds for crop protection and enhancement of agricultural yields.
Used in Organic Synthesis Research:
(1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate is also used as a starting material in academic and industrial research for organic synthesis. Its chiral nature and protected amine group make it an attractive candidate for exploring new synthetic pathways and developing innovative methodologies in organic chemistry.
Used in the Synthesis of Bioactive Molecules:
(1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate is employed as a precursor in the synthesis of bioactive molecules, which have potential applications in medicine, biotechnology, and other life sciences. The versatility of (1S,3R)-methyl 3-(tert-butoxycarbonylamino)cyclohexanecarboxylate allows for the generation of a diverse range of bioactive compounds with possible applications in treating diseases or as probes in biological research.

Upstream product

• 222530-34-9 (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclo hexane-1-carboxylic acid 
• 74-88-4 methyl iodide 
• 222530-39-4 (1R,3S)-3-(tert-butoxycarbonylamino)aminocyclohexanecarboxylic acid 
• 202120-10-3 (1S,3R)-3-aminocyclohexylcarboxylic acid methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

Pyrimidopyrazole compound, preparation method and application thereof

The invention discloses a pyrimidopyrazole compound, a preparation method and application thereof. The invention provides a pyrimidopyrazole compound shown as formula I or pharmaceutically acceptablesalts thereof. The compound has a relatively good inhibition effect on CDK7.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and/or inhibit transcription in the subject.

INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing' s sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

Methods for inhibiting protein kinases

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevent

NOVEL SULFONE AMIDE DERIVATIVES CAPABLE OF INHIBITING BACE

The present invention relates to novel derivatives of sulfone amide of Formula 1 as defined in this disclosure which inhibit the activity of BACE (or beta-secretase). These sulfone amide derivatives are useful for the treatment and prevention of Alzheimer's disease and related diseases caused by production of beta-amyloid, by inhibiting the activity of BACE.